The latest price target for Vanda Pharma (NASDAQ:VNDA) was reported by Cantor Fitzgerald on August 1, 2024. The analyst firm set a price target for $13.00 expecting VNDA to rise to within 12 months (a possible 159.48% upside). 2 analyst firms have reported ratings in the last year.

The latest analyst rating for Vanda Pharma (NASDAQ:VNDA) was provided by Cantor Fitzgerald, and Vanda Pharma maintained their overweight rating.

There is no last upgrade for Vanda Pharma

The last downgrade for Vanda Pharmaceuticals Inc happened on February 25, 2022 when Jefferies changed their price target from $24 to $12 for Vanda Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vanda Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vanda Pharma was filed on August 1, 2024 so you should expect the next rating to be made available sometime around August 1, 2025.

While ratings are subjective and will change, the latest Vanda Pharma (VNDA) rating was a maintained with a price target of $11.00 to $13.00. The current price Vanda Pharma (VNDA) is trading at is $5.01, which is out of the analyst’s predicted range.